PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.\', \'Tayside Cancer Centre, Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK.\', \'NHS Lanarkshire, South Lanarkshire, UK.\', \'Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.\', \'Edinburgh Cancer Centre, NHS Lothian, Edinburgh, UK.\', \'NHS Grampian, Aberdeen, UK.\', \'West of Scotland Cancer Network, Glasgow, UK.\', \'NHS Highland, Inverness, UK.\', \'Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK. r.petty@dundee.ac.uk.\', \'Tayside Cancer Centre, Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK. r.petty@dundee.ac.uk.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41416-021-01262-8
?:hasPublicationType
?:journal
  • British journal of cancer
is ?:pmid of
?:pmid
?:pmid
  • 33526866
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.89
?:rankingScore_hIndex
  • 204
?:title
  • The impact of COVID-19 on systemic anticancer treatment delivery in Scotland.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all